JPMorgan’s 5.2% Neurocrine (NBIX) stake disclosed in Schedule 13G filing

Rhea-AI Filing Summary

JPMorgan Chase & Co. has filed a Schedule 13G reporting a passive ownership stake in Neurocrine Biosciences, Inc. common stock. As of 12/31/2025, JPMorgan reports beneficial ownership of 5,198,084 shares, representing 5.2% of Neurocrine’s common stock.

The filing shows JPMorgan has sole voting power over 4,705,046 shares and shared voting power over 21,535 shares. It has sole dispositive power over 5,196,778 shares and shared dispositive power over 1,221 shares. JPMorgan is identified as a Delaware holding company with several subsidiaries, including J.P. Morgan Securities LLC and JPMorgan Chase Bank, National Association.

JPMorgan certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Neurocrine Biosciences.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

NEUROCRINE BIOSCIENCES, INC.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

64125C109

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 64125C109

1

Names of Reporting Persons

JPMORGAN CHASE & CO.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,705,046.00
6	Shared Voting Power 21,535.00
7	Sole Dispositive Power 5,196,778.00
8	Shared Dispositive Power 1,221.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,198,084.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NEUROCRINE BIOSCIENCES, INC.
(b)	Address of issuer's principal executive offices: 6027 Edgewood Bend Court San Diego CA 92130
Item 2.
(a)	Name of person filing: JPMORGAN CHASE & CO.
(b)	Address or principal business office or, if none, residence: 270 Park Avenue,,New York, NY 10017
(c)	Citizenship: DE
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 64125C109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5198084
(b)	Percent of class: 5.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4705046
	(ii) Shared power to vote or to direct the vote: 21535
	(iii) Sole power to dispose or to direct the disposition of: 5196778
	(iv) Shared power to dispose or to direct the disposition of: 1221
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. J.P. Morgan Trust Company of Delaware; J.P. Morgan Securities LLC; JPMorgan Asset Management (UK) Limited; J.P. MORGAN SE; JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.; J.P. Morgan Mansart Management Limited; 55I, LLC
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. Not Applicable
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JPMORGAN CHASE & CO.

Signature:	Rachel Tsvaygoft
Name/Title:	Vice President
Date:	01/21/2026

FAQ

What percentage of Neurocrine Biosciences (NBIX) does JPMorgan Chase & Co. report owning?

JPMorgan Chase & Co. reports beneficial ownership of 5.2% of Neurocrine Biosciences, Inc.’s common stock as disclosed in the Schedule 13G.

How many Neurocrine Biosciences (NBIX) shares does JPMorgan Chase & Co. beneficially own?

JPMorgan Chase & Co. reports beneficial ownership of 5,198,084 shares of Neurocrine Biosciences, Inc. common stock.

How is JPMorgan’s voting power over Neurocrine Biosciences (NBIX) shares structured?

JPMorgan has 4,705,046 shares with sole voting power and 21,535 shares with shared voting power in Neurocrine Biosciences, Inc.

What dispositive powers does JPMorgan have over its Neurocrine Biosciences (NBIX) holdings?

JPMorgan has sole dispositive power over 5,196,778 shares and shared dispositive power over 1,221 shares of Neurocrine Biosciences, Inc. common stock.

Is JPMorgan’s stake in Neurocrine Biosciences (NBIX) reported as passive or for control purposes?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Neurocrine Biosciences, Inc.

When was JPMorgan’s ownership position in Neurocrine Biosciences (NBIX) measured for this Schedule 13G?

The ownership position is stated as of the 12/31/2025 event date in the Schedule 13G.

What type of reporting person is JPMorgan in this Neurocrine Biosciences (NBIX) filing?

JPMorgan Chase & Co. is classified as an HC, indicating a parent holding company or control person, and is organized in Delaware.